ClinicalTrials.gg
RecruitingNCT07643779Updated Nov 9, 2026

Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux Disease

An observational study in Gastroesophageal Reflux Disease (GERD), Symptom and Musculoskeletal Pain, sponsored by Karabuk University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Karabuk University · Observational

How we know

Updated Nov 9, 2026Now RecruitingFirst site in Turkey (Türkiye)+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
51
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Gastroesophageal Reflux with a site in Turkey — 2 open to participants now, 3 under way, none of them phase 3. Gastroesophageal Reflux · Turkey.

Started
2026
the only one that year
Observational
5 of 18
2 open now
Registered
18th of 18
by date
Lead sponsor
2 of 18
Karabuk University

Among the 18 studies in Gastroesophageal Reflux with a site in Turkey, this one is the only one that started in 2026, is one of 5 observational ones, and was the 18th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

2 of the 18 studies in Gastroesophageal Reflux with a site in Turkey are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Gastroesophageal Reflux with a site in Turkey, or all of them as a file.
02

Study summary

This study is a cross-sectional research designed to investigate symptom severity, posture, musculoskeletal pain, and physical activity levels in individuals with gastroesophageal reflux disease (GERD).

Read the detailed description

Symptom severity will be assessed using the GERD-Q and PROMIS GERD scales. Postural assessment will be performed using the Posture Screen Lite application. Musculoskeletal pain will be evaluated with the Visual Analog Scale (VAS) and a body diagram, while physical activity levels will be measured using the International Physical Activity Questionnaire (IPAQ).

The aim of the study is to determine whether GERD is associated not only with gastrointestinal symptoms but also with functional parameters such as posture, pain, and physical activity level.

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)
  • Symptom
  • Musculoskeletal Pain
  • Physical Activity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with and without Gastroesophageal Reflux Disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being diagnosed with gastroesophageal reflux disease (GERD)
  • Age between 18 and 65 years
  • Willingness to participate in the study assessments

Exclusion criteria

Exclusion Criteria:

  • Presence of a diagnosed psychiatric disorder
  • Pregnancy or breastfeeding status
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
51 participants (estimated)
Patient registry
No

Groups and cohorts

  • GERD patient group

    Age between 18 and 65 years patient who has GERD

  • control group

    Age between 18 and 65 years patient who has not GERD

06

What researchers measure

Primary outcomes

  1. Gastroesophageal Reflux Disease Questionnaire (GERD-Q)

    The GERD-Q is a six-item Likert-type questionnaire that assesses the frequency of GERD-related symptoms over the past week. The first four items evaluate symptom frequency and are used for the diagnosis of the disease and monitoring treatment response. The remaining two items assess the impact of the disease on daily life, including over-the-counter medication use and sleep disturbance. Each item is scored on a four-point scale ranging from 0 to 3 according to symptom frequency. In items 1, 2, 5, and 6, scores increase from 0 to 3 with increasing symptom frequency, whereas in items 3 and 4, scoring is reversed.

    Time frame: 1 day

  2. PROMIS GERD Scale

    The PROMIS GERD scale consists of 13 items. Each item is scored on a scale ranging from 0 to 4 points, and the total score is obtained by summing all item scores. According to the original scoring system, a score of 0 indicates no symptoms, scores of 1-3 indicate minimal symptoms, scores of 4-7 indicate mild symptoms, scores of 8-15 indicate moderate symptoms, and scores of 16 and above indicate severe symptoms.

    Time frame: 1 day

  3. Postural Analysis

    Posture Screen Lite is a posture analysis, body composition, and movement assessment software designed for use on iOS and Android devices with built-in camera systems. In this study, posture will be assessed using the iPad-based Posture Screen Lite application. Participants will be assessed wearing appropriate clothing that leaves the upper trunk and lower legs exposed. Photographs will be taken from anterior, posterior, and right and left lateral views using a smartphone, without placing reference markers on the participant beforehand. The captured images will then be analyzed using the Posture Screen Lite software by identifying anatomical reference points on the photographs.

    Time frame: 1 day

  4. Visual Analog Scale (VAS)

    The Visual Analog Scale (VAS) will be used to assess pain intensity. VAS has been shown to be a valid and reliable method that is sensitive to small changes in clinical pain and treatment-related pain intensity. Participants will be asked to indicate their pain level on a 10-cm horizontal line, ranging from "0" (no pain) to "10" (worst imaginable pain). In addition, participants will mark the location(s) of their pain on a body diagram to determine pain distribution and localization.

    Time frame: 1 day

  5. International Physical Activity Questionnaire (IPAQ)

    The International Physical Activity Questionnaire (IPAQ) was developed by Craig et al. (2003) to assess physical activity levels. The short form consists of seven items and evaluates physical activity performed during the last seven days. Only activities lasting at least 10 minutes at a time are considered. Participants report the duration (in minutes) of vigorous activities (e.g., weight lifting, fast cycling, aerobic exercises, team sports), moderate activities (e.g., table tennis, folk dances, light load carrying), and walking. These values are converted into metabolic equivalent (MET) scores, and total physical activity level is calculated as MET-min/week. Based on the results, participants can be classified as inactive, minimally active, or highly active.

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.

Of 95 non-industry observational studies under Gastroesophageal Reflux, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 167. This study's planned 3 months is below that.

Counting every sponsor, half of 117 studies reached it within 45 months; a quarter within 17 and three quarters within 134.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Jul 2026 → Nov 2026, primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2026
First posted
Jun 12, 2026
StartEst.
Nov 12, 2026was Jul 2026
Primary completionEst.
Mar 1, 2027was Dec 2026
CompletionEst.
Apr 1, 2027was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 9, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Karabuk University · Karabük, Turkey (Türkiye)
Nov 9, 2026
Start date
Jul 1, 2026→Nov 12, 2026
Nov 9, 2026
Primary completion
Dec 30, 2026→Mar 1, 2027
Nov 9, 2026
Study completion
Dec 30, 2026→Apr 1, 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Karabuk University · Karabük, Turkey (Türkiye)
    Start date Jul 1, 2026→Nov 12, 2026
    Primary completion Dec 30, 2026→Mar 1, 2027
    Study completion Dec 30, 2026→Apr 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07643779
Lead sponsor
Karabuk University
Responsible party
Nurcan Contarli (Doctor, Karabuk University) — Principal investigator
First posted
Jun 12, 2026
Start date
Nov 12, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Nurcan Contarli, PhD
Contact
nurcancontarli@karabuk.edu.tr
+90 370 418 9171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion